Studying the effects of polycyclic aromatic hydrocarbons on peripheral arterial disease in the United States.

PURPOSE Polycyclic aromatic hydrocarbons are a group of prevalent pollutants which are produced by incomplete combustion of organic materials such as coal, fuel, tobacco smoking and food cooking. The associations between exposures to polycyclic aromatic hydrocarbons (PAHs) and peripheral arterial disease (PAD) have not been well studied. METHODS We used the 2001-2004 National Health and Nutrition Examination Survey (NHANES) to investigate the associations between eight monohydroxy urinary metabolites of four PAHs and PAD. RESULTS In a logistic regression model, subjects within the middle and highest tertiles of fluorene metabolites, 2-hydroxyfluorene (2-FLUO) and 3-hydroxyfluorene (3-FLUO), and phenanthrene metabolites, 1-hydroxyphenanthrene (1-PHEN) and 2-hydroxyphenanthrene (2-PHEN), had significantly higher prevalence of PAD as compared to subjects within the lowest tertile after adjusting for cigarette smoking, diabetes mellitus and other covariates (For 2-FLUO, the 3rd tertile: OR=2.22, 95% CI=1.13-4.37, p for trend=0.02; For 3-FLUO, the 3rd tertile: OR=2.36, 95% CI: 1.16-4.77, p for trend=0.02; For 1-PHEN, the 3rd tertile: OR=1.84, 95% CI: 1.01-3.37, p for trend=0.04; For 2-PHEN, the 3rd tertile: OR=1.76, 95% CI: 1.07-2.88, p for trend=0.03). CONCLUSIONS Our findings suggest that exposure to PAHs may increase the risk of PAD. Further studies are necessary to explore the associations between PAHs and PAD.

[1]  W. Ahrens,et al.  Polycyclic Aromatic Hydrocarbons and Fatal Ischemic Heart Disease , 2005, Epidemiology.

[2]  Liping Li,et al.  Study on the Association between Ambient Air Pollution and Daily Cardiovascular and Respiratory Mortality in an Urban District of Beijing , 2011, International journal of environmental research and public health.

[3]  P. Libby,et al.  Inflammation and Atherosclerosis , 2002, Circulation.

[4]  H. Kan,et al.  Studying associations between urinary metabolites of polycyclic aromatic hydrocarbons (PAHs) and cardiovascular diseases in the United States. , 2010, The Science of the total environment.

[5]  M. Criqui,et al.  Peripheral arterial disease detection, awareness, and treatment in primary care. , 2001, JAMA.

[6]  J. Albrecht,et al.  Induction of cytochrome CYPIA1 and formation of toxic metabolites of benzo[a]pyrene by rat aorta: a possible role in atherogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[7]  E. Tuzcu,et al.  Peripheral arterial disease and progression of coronary atherosclerosis. , 2011, Journal of the American College of Cardiology.

[8]  Eric J Topol,et al.  Critical issues in peripheral arterial disease detection and management: a call to action. , 2003, Archives of internal medicine.

[9]  M. Hajaligol,et al.  Formation of polycyclic aromatic hydrocarbons from tobacco: the link between low temperature residual solid (char) and PAH formation. , 2007, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[10]  Elizabeth Selvin,et al.  Prevalence of and Risk Factors for Peripheral Arterial Disease in the United States: Results From the National Health and Nutrition Examination Survey, 1999–2000 , 2004, Circulation.

[11]  Daniel Krewski,et al.  Lung Cancer and Cardiovascular Disease Mortality Associated with Ambient Air Pollution and Cigarette Smoke: Shape of the Exposure–Response Relationships , 2011, Environmental health perspectives.

[12]  F. Jongeneelen,et al.  Dermal exposure to polycyclic aromatic hydrocarbons among primary aluminium workers. , 1992, La Medicina del lavoro.

[13]  R. Sram,et al.  DNA-adducts and atherosclerosis: a study of accidental and sudden death males in the Czech Republic. , 2002, Mutation research.

[14]  A. Berglund,et al.  Increased smooth muscle cell proliferation by dimethylbenzanthracene is correlated to variations in activity of ornithine decarboxylase but not arylhydrocarbonhydroxylase. , 1991, Artery.

[15]  K. Kelsey,et al.  Urinary 1-hydroxypyrene and polycyclic aromatic hydrocarbon exposure among asphalt paving workers. , 2004, The Annals of occupational hygiene.

[16]  J. Schwartz,et al.  Immunohistochemical detection of polycyclic aromatic hydrocarbon-DNA damage in human blood vessels of smokers and non-smokers. , 1998, Atherosclerosis.

[17]  H. Notø,et al.  Correlation between urinary 1-hydroxypyrene and ambient air pyrene measured with an inhalable aerosol sampler and a total dust sampler in an electrode paste plant. , 1998, The Science of the total environment.

[18]  J. Hobbs,et al.  Ankle systolic pressure measurements in arterial disease affecting the lower extremities , 1969, The British journal of surgery.

[19]  E. Topol,et al.  C-reactive protein: a 'golden marker' for inflammation and coronary artery disease. , 2001, Cleveland Clinic journal of medicine.

[20]  H. Yamazaki,et al.  Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. , 1996, Cancer research.

[21]  L Stavenow,et al.  Effects of polycyclic aromatic hydrocarbons on proliferation, collagen secretion and viability of arterial smooth muscle cells in culture. , 1988, Artery.

[22]  Tom Greene,et al.  Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.

[23]  T. Kamataki,et al.  CYP1A1-mediated mechanism for atherosclerosis induced by polycyclic aromatic hydrocarbons. , 2005, Biochemical and biophysical research communications.

[24]  M. Mumtaz,et al.  Atsdr Evaluation of Health Effects of Chemicals. Iv. Polycyclic Aromatic Hydrocarbons (PAHs): Understanding a Complex Problem , 1996, Toxicology and industrial health.

[25]  R. Albert,et al.  Effect of carcinogens on chicken atherosclerosis. , 1977, Cancer research.

[26]  Zheng Li,et al.  Measurement of urinary monohydroxy polycyclic aromatic hydrocarbons using automated liquid-liquid extraction and gas chromatography/isotope dilution high-resolution mass spectrometry. , 2006, Analytical chemistry.

[27]  K. Ramos,et al.  Bioactivation of Polycyclic Aromatic Hydrocarbon Carcinogens within the vascular Wall: Implications for Human Atherogenesis , 2005, Drug metabolism reviews.

[28]  W. M. R. Günther,et al.  PAH biomarkers for human health risk assessment: a review of the state-of-the-art. , 2008, Cadernos de saude publica.

[29]  E. Benditt,et al.  Evidence for a monoclonal origin of human atherosclerotic plaques. , 1973, Proceedings of the National Academy of Sciences of the United States of America.

[30]  A. Mainous,et al.  Association of urinary polycyclic aromatic hydrocarbons and serum C-reactive protein. , 2010, Environmental Research.

[31]  M. Daemen,et al.  Polycyclic aromatic hydrocarbons induce an inflammatory atherosclerotic plaque phenotype irrespective of their DNA binding properties , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  H. Gornik,et al.  Using the ankle-brachial index to diagnose peripheral artery disease and assess cardiovascular risk , 2012, Cleveland Clinic Journal of Medicine.

[33]  Elizabeth Selvin,et al.  Prevalence of and Risk Factors for Peripheral Arterial Disease in the United States: Results From the National Health and Nutrition Examination Survey, 1999–2000 , 2004 .

[34]  J. Polak,et al.  Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. , 1993, Circulation.

[35]  T. Kamataki,et al.  Activation of p53 as a causal step for atherosclerosis induced by polycyclic aromatic hydrocarbons , 2006, FEBS letters.

[36]  L. Sharma,et al.  Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. , 2001, JAMA.